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Background: In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival
benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life
(HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial’s
12 week treatment induction period.
Methods: The Phase III clinical trial (MDX010-20) was a double-blind, fixed dose study in 676 previously treated
advanced unresectable stage III or IV melanoma patients. Patients were randomized 3:1:1 to receive either
ipilimumab (3 mg/kg q3w x 4 doses) + gp100 (peptide vaccine; 1 mg q3w x 4 doses; ipilimumab plus gp100,
n = 403); gp100 vaccine + placebo (gp100 alone, n = 136); or ipilimumab + placebo (ipilimumab alone, n = 137). The
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
assessed HRQL. Baseline to Week 12 changes in EORTC QLQ-C30 function, global health status, and symptom
scores were analyzed for ipilimumab with/without gp100 vaccine compared to gp100 alone. Mean change in
scores were categorized “no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “very much”
(>20).
Results: In the ipilimumab plus gp100 and ipilimumab alone groups, mean changes from baseline to Week 12
generally indicated “no change” or “a little” impairment across EORTC QLQ-C30 global health status, function, and
symptom subscales. Significant differences in constipation, favoring ipilimumab, were observed (p< 0.05). For
ipilimumab alone arm, subscales with no or a little impairment were physical, emotional, cognitive, social function,
global health, nausea, pain, dyspnea, constipation, and diarrhea subscales. For the gp100 alone group, the observed
changes were moderate to large for global health, role function, fatigue, and for pain.
Conclusions: Ipilimumab with/without gp100 vaccine does not have a significant negative HRQL impact during
the treatment induction phase relative to gp100 alone in stage III or IV melanoma patients.
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Advanced melanoma is a serious and life threatening can-
cer which has an impact on health-related quality of life
(HRQL). According to the American Cancer Society, there
were an estimated 68,130 new cases of melanoma and
8,700 deaths in the US in 2010, which accounts for almost
three-fourths of all skin cancer deaths [1]. The median
overall survival for patients with untreated advanced mel-
anoma ranges between 6 to 9 months [1-6]. Cornish et al.
recently demonstrated that the impact of melanoma on
patient HRQL is comparable with other cancers [7].
Until the recent approvals for vemurafenib and ipilimu-
mab, none of the currently approved treatments for
advanced melanoma have shown overall survival benefit
[3,8-18]. The focus of current treatment is on improving
survival, managing symptoms, and improving HRQL out-
comes [2,19]. Studies have shown that melanoma impacts
psychological functioning (i.e., anxiety, depression, and
vulnerability) [20-24]. In studies of advanced melanoma
patients receiving treatment, melanoma patients also
reported significant impairments in physical functioning
and fatigue symptoms [20,25,26]. Treatment-related
HRQL outcomes vary by HRQL instrument, study meth-
ods and design, study dropout rates, and disease progres-
sion rates. These factors need to be taken into
consideration when interpreting the findings of HRQL
studies in advanced melanoma.
Several clinical trials comparing treatments for advanced
melanoma have included HRQL measures [14,20,26-36].
In general, these clinical studies demonstrate varied
HRQL and symptom effects for different treatments, al-
though the earliest studies demonstrate significant impair-
ment to functioning [34,35]. However, most of these
studies have considerable dropout rates and results are
often restricted to the initial weeks of the clinical trial
study. Dropouts are frequently observed in patients with
significant toxicity or disease progression, and these miss-
ing data can make the follow-up HRQL outcomes appear
better than they are in reality [37].
Ipilimumab is an anti-CTLA-4 monoclonal antibody
with anti-tumor activity and has demonstrated statistically
significant improvement in overall survival in a Phase III
study (MDX010-20) in patients with previously treated
unresectable stage III or IV melanoma [9]. Efficacy and
safety data corresponding to the Phase II and III clinical
trials in advanced melanoma have been reported else-
where [9,12,38]. Overall, ipilimumab, alone or in combin-
ation with gp100, was tolerable in subjects with advanced
metastatic melanoma with a generally manageable safety
profile, which is consistent with safety demonstrated in
previous studies of ipilimumab [9]. Study drug-related ad-
verse events, regardless of etiology, were severe (≥ Grade
3) for 19.5%, 26.0%, and 12.1% of subjects treated with ipi-
limumab plus gp100, ipilimumab alone, and gp100 alone,respectively [9]. Immune-related adverse events were the
most frequently reported drug-related adverse events [9].
The immune-related adverse events of ipilimumab are
managed through administration of systemic glucocorti-
coids and other immunosuppressant agents along with ad-
herence to treatment according to well established
guidelines [39,40]. The majority of these immune-related
adverse events occurred during the induction period of
ipilimumab treatment. This report summarizes the HRQL
outcomes during the 12 week treatment induction period
of the ipilimumab Phase III clinical trial (MDX010-20).
Assessment of the effects of ipilimumab in relation to
overall HRQL is important and will allow oncologists to
appropriately educate patients on the risks and benefits of
treatment with this agent.Methods
Study design
Study MDX010-20 was conducted in accordance with
International Conference on Harmonisation-Good Clin-
ical Practices and the Declaration of Helsinki. The study
was approved by local regulatory authorities and institu-
tional review boards and Ethics Committees at the partici-
pating sites, and all subjects provided written consent.
The Phase III clinical trial (MDX010-20) was a double-
blind, fixed dose study in 676 previously treated patients
with advanced stage III or IV melanoma [9]. Patients in
this trial were randomized 3:1:1 to receive either ipilimu-
mab (3 mg/kg q3w x 4 doses) + gp100 (peptide vaccine;
1 mg q3w x 4 doses; ipilimumab plus gpl00, n= 403);
gp100 vaccine+ placebo (gp100 alone, n = 136); or ipilimu-
mab+placebo (ipilimumab alone, n = 137). The main in-
clusion criteria were men and women aged ≥18 years,
histological confirmed advanced stage III or IV melanoma,
Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0 or 1, and life expectancy of at least four
months. Key exclusion criteria included active symptom-
atic or asymptomatic untreated central nervous system
(CNS) metastasis, primary ocular melanoma, or pregnant
or breastfeeding women. Patients with stable, pre-treated
CNS metastases were allowed in the study.Treatment regimen
Ipilimumab, at a dose of 3 mg per kilogram of body
weight, was administered with or without gp100 every
three weeks for up to four treatments (induction) [9]. In
the gp100 groups, patients received two modified HLA-
A* 0201-restricted peptides with incomplete Freund’s
adjuvant (Montanide ISA-51): a gp100:209-217(210M)
peptide, 1 mg injected in the right anterior thigh, and a
gp100:280-288(288V) peptide, 1 mg injected in the left
anterior thigh. These injections were given immediately
after the intravenous infusion of ipilimumab or placebo.
Table 1 Baseline demographics and clinical characteristics
Phase III (MDX010-20)
Ipilimumab
plus gp100
Ipilimumab
Alone
gp100
Alone
Total
(N = 403) (N = 137) (N = 136) (N= 676)
Age (years), mean 55.6 56.8 57.4 56.2
Gender, n (%)
Male 247 (61) 81 (59) 73 (54) 401 (59)
Melanoma stage,
n (%)
M0 5 (1.2) 1 (0.7) 4 (2.9) 10 (1.5)
M1a 37 (9.2) 14 (10.2) 11 (8.1) 62 (9.2)
M1b 76 (18.9) 22 (16.1) 23 (16.9) 121 (17.9)
M1c 285 (70.7) 100 (73.0) 98 (72.1) 483 (71.4)
Prior treatment
for advanced
melanoma, n (%)
403 (100.0) 137 (100.0) 136 (100.0) 676 (100.0)
ECOG PS, n (%)
0 233 (57.8) 72 (52.6) 70 (51.5) 375 (55.5)
1 165 (40.9) 64 (46.7) 61 (44.9) 290 (42.9)
2 or 3 5 (1.2) 1 (0.7) 4 (2.9) 10 (1.4)
Missing 0 0 1 (0.7) 1 (0.1)
CNS metastases
at baseline, n (%)
46 (11.4) 15 (10.9) 21 (15.4) 82 (12.1)
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itional treatment was received at Weeks 4, 7, and 10 if
there was no intolerable toxicity, no rapidly progressive
disease, and no significant decline in performance status.
This included patients who developed new lesions and/or
experienced growth in baseline lesions. Patients were
offered additional courses of therapy (reinduction) if they
had stable disease after Week 12 or a confirmed partial or
complete response and no dose-limiting toxicity, or if they
had disease progression with their assigned treatment
regimen [9].
Health-related quality of life measure
HRQL was evaluated using the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30) [41,42]. The EORTC
QLQ-C30 contains subscales for global health status,
and physical, emotional, role, cognitive, and social func-
tion, with higher scores indicating better functioning
[41,42]. Symptom subscales include pain, nausea/vomit-
ing, fatigue, dyspnea, appetite loss, insomnia, diarrhea,
and constipation (higher scores indicate greater symp-
tom severity). Extensive evidence is available supporting
the reliability, validity, and responsiveness of the EORTC
QLQ-C30 in different cancer populations [42,43]. In the
Phase III trial (MDX010-20), HRQL outcomes were self-
administered at the clinical centers before any clinical
procedures or physician interactions, including any dis-
cussion of imaging studies at baseline and Week 12.
Statistical analyses
Baseline to Week 12 changes in EORTC QLQ-C30 func-
tion, global health status and symptom scores were calcu-
lated. Analysis of variance models were used to compare
treatment differences for the HRQL outcomes. Since there
is clinical interest in effectiveness and risks in older oncol-
ogy patients, post hoc subgroup analysis of EORTC QLQ-
C30 data by age (<65 years versus ≥65 years) was also
conducted, and these analyses were compared to the
results from the total sample (i.e., combined age group).
Descriptive analyses are reported for the data, and no stat-
istical tests were performed due to the ad hoc nature and
relatively small sample sizes. Interpretations of the mean
change in scores were categorized as “no change” (0–5
points), “a little” (5–10 points), “moderate” (10–20 points),
and “very much” (>20 points), based on Osoba et al. [44].
When function and symptom scores showed either “no
change” or “little change,” they were interpreted as reflect-
ing no or minimal impact on patient HRQL [44].
Results
Demographic and clinical characteristics
Patients were randomly assigned to either the ipilimu-
mab plus gp100 (n = 403), ipilimumab alone (n = 137),and gp100 alone (n = 136) treatment arms. Participants
from all three arms (total n = 676) had a mean age of
56.2 ± 57.0 years and 59% were male (Table 1). The ma-
jority of participants had M1C stage at entry (n = 483;
71.4%) and almost all had an ECOG performance status
score of 0 or 1 (n = 665; 98.4%). All of the participants
had received prior treatment for advanced melanoma.
Twelve percent of participants (n = 82; 12.1%) had CNS
metastases at baseline.
HRQL outcomes
In the Phase III study (MDX010-20), 95% had baseline
HRQL assessments and Week 12 assessments were
available for 236 (62%), 85 (65%), and 80 (61%) of the
patients treated with ipilimumab plus gp100, ipilimumab
alone, and gp100 alone, respectively. Missing HRQL data
at baseline were due to administrative errors. Reasons
for missing Week 12 data were primarily due to disease
progression, adverse events, or death [9]. There were no
differences in demographic or relevant clinical character-
istics between those study patients with complete and
missing Week 12 HRQL assessments. There were differ-
ences in baseline EORTC QLQ-C30 scores for global,
physical, role, emotional, and social function scores and
for fatigue, nausea, pain, dyspnea, sleep, appetite, and
constipation scores between those with and without
Week 12 assessments.
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baseline to Week 12 changes were no greater than minimal
in the “a little” impairment category (Figures 1 and 2).
There was a statistically significant difference in constipa-
tion scores between the ipilimumab plus gp100 and the
gp100 alone groups (p< 0.05) and between the ipilimumab
alone and gp100 alone groups (p< 0.05). None of the other
differences in HRQL scores between the three treatments
were statistically significant.
For the ipilimumab plus gp100 arm, the observed impair-
ments were in the “no change” or “a little” categories for
physical, role, emotional, cognitive, and social function, glo-
bal health, nausea, pain, dyspnea, sleep disturbance, appetite
loss, constipation, and diarrhea subscales. For the ipilimu-
mab alone group, the observed impairments were in the
“no change” or “a little” categories for the physical, emo-
tional, cognitive, and social function, the global health, nau-
sea, pain, dyspnea, constipation, and diarrhea subscales. For
the gp100 alone group, the observed impairments were in
the “no change” or “a little” categories for the cognitive and
social function, nausea, dyspnea, and diarrhea subscales. In
the gp100 alone group, moderate to large impairments were
seen for global health, role function, fatigue, and pain.
Due to interest from clinicians in the analysis of
results for older oncology patients, results from the post
hoc subgroup analysis of EORTC QLQ-C30 data were
also compared by two age groups: patients aged
<65 years and those ≥65 years (Table 2). For patients
<65 years, in the ipilimumab plus gp100 arm, there wereFigure 1 Baseline to Week 12 endpoint changes in EORTC QLQ-C30 fu
global health scales, improvements are indicated by positive scores. ** p>
“no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “vnone to small impairments in functional outcomes and
symptom scores, while the older age group reported a
similar pattern of changes for most of the outcomes.
Older patients reported moderate impairments in role
function, global health, fatigue and sleep disturbance. In
the ipilimumab alone subgroup of patients <65 years,
the impairment changes in functional outcomes and
symptom scores were none to small for most scores, ex-
cept for fatigue and appetite loss. For patients aged
≥65 years, in the ipilimumab alone group, moderate or
greater impairments were seen in social function and
global health, which differed somewhat from the younger
age group. More symptom effects were observed in those
≥65 years for dyspnea and diarrhea compared with the
<65 age group. These findings need to be interpreted cau-
tiously given the smaller sample size.
Discussion
Ipilimumab at 3 mg/kg monotherapy, whether combined
with gp100 vaccine or not, was associated with a 19% to
36% reduction in the rate of disease progression and,
more importantly, had increased overall survival com-
pared with the gp100 vaccine alone group in patients
with previously treated advanced melanoma [9]. In gen-
eral, the HRQL results for the ipilimumab groups dem-
onstrate that ipilimumab treatment is associated with
minimal impairments on functioning and symptoms
during the treatment induction period. The only statisti-
cally significant difference between ipilimumab andnction and global health status scores. * For the functioning and
0.05 for all comparisons. Mean change in scores were categorized as
ery much” (>20).
Figure 2 Baseline to Week 12 endpoint changes in EORTC QLQ-C30 symptom scores. * For symptom scales, improvements are indicated
by negative scores. ** p< 0.05 versus gp100 group. *** p> 0.05 for all comparisons (except for Constipation with p< 0.05). Mean change in
scores were categorized as “no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “very much” (>20).
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be due to increased rate of colitis in the ipilimumab
groups (5.3-7.6% versus 0.8%) [9]. Most of the observed
changes were in the range of “no change” or minimal
impairments, which indicates that HRQL was main-
tained during the treatment induction period. Function-
ing and symptom scores did not improve during
treatment; only the overall HRQL of these patients was
negatively impacted to a small extent. The gp100 groupTable 2 Baseline to week 12 endpoint changes in EORTC QLQ
Ipilimumab plus gp100 Ipilimumab
< 65 years ≥ 65 years
(N= 170) (N = 66)
Physical function −6.2 −9.5
Role function −9.8 −11.7
Emotional function −0.8 −6.2
Cognitive function −3.9 −4.7
Social function −5.4 −7.4
Global health −6.5 −12.1
Fatigue 9 14.2
Nausea/vomiting 5.3 7.3
Pain 7.2 6.4
Dyspnea 2 8.1
Sleep disturbance 5 10.4
Appetite loss 9.4 9.6
Constipation 3.8 6
Diarrhea 6.2 7.7reported increased pain, fatigue, dyspnea, and decreased
physical and role function compared with the ipilimu-
mab group.
After 12 weeks of treatment with ipilimumab, only fa-
tigue, sleep disturbance, and appetite loss showed mod-
erate impairments. However, there was no significant
negative impact on physical, emotional, cognitive, and
social functioning and global health status in the ipili-
mumab treated groups. These findings indicate that-C30 scores by age groups
plus gp100 Ipilimumab Alone Ipilimumab Alone
< 65 years ≥ 65 years
(N= 59) (N= 26)
−4.3 −9.3
−11 −12.9
−2.2 −9.3
−3.6 −8.8
−6 −12.3
−6 −17
12.4 12.1
4.9 3.1
10 7.4
2.1 12.5
8.8 12.9
12.9 11.7
2.3 −0.4
7.7 13.5
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mab treatment. Therefore, the trade-offs between
extended survival and HRQL may be acceptable to
patients and their clinicians [45]. Given that few treat-
ments for advanced melanoma (i.e., vemurafenib and ipi-
limumab) are associated with improvements in overall
survival [9,10,12,13], these HRQL results for ipilimumab
are very encouraging.
We identified three studies that used the EORTC
QLQ-C30 comparing treatments for advanced melan-
oma [14,32,34]. Study design and methods are summar-
ized in Additional file 1 Table A1. Two of these studies
reported higher rates of missing HRQL data at follow-
up compared with ipilimumab plus gp100 or ipilimu-
mab alone (Additional file 1 Table A2). Disease progres-
sion rates were somewhat greater in the comparison
studies, ranging from 61% to 74% (Additional file 1
Table A2). For the EORTC QLQ-C30 functional out-
comes, dacarbazine-videsine-cisplatin and dacarbazine-
videsine treated groups demonstrated worse global health
and physical, role, and social function compared with ipili-
mumab plus gp100 or ipilimumab alone groups (Additional
file 2 Figure A1). For the symptom outcomes, dacarbazine-
videsine-cisplatin and dacarbazine-videsine treated
groups demonstrated worse fatigue, nausea/vomiting,
and appetite loss and similar pain compared with ipilimu-
mab plus gp100 and ipilimumab alone groups (Additional
file 3 Figure A2). The studies by Avril et al. [14] and
Kiebert et al. [32] showed changes in EORTC QLQ-C30
function and symptom scores comparable to the ipilimu-
mab plus gp100 and ipilimumab alone treatment groups.
Overall, the ipilimumab HRQL effects we observed may
be better or comparable to those observed in these other
clinical trials, as supported by little meaningful impair-
ment in functioning and symptoms during the treatment
induction period.
The comparison of HRQL outcomes between the ipili-
mumab clinical trials and these other studies should be
interpreted cautiously given the differences in methods,
disease progression, and dropout rates. Significant differ-
ences in mechanism of action and known toxicity pro-
files of chemotherapy and ipilimumab may contribute to
observed differences in HRQL between the chemother-
apy and ipilimumab. In addition, ipilimumab’s demon-
strated efficacy compared to the general lack of
chemotherapy activity in this disease is another consid-
eration for observed differences.
In the Phase II study for ipilimumab [38], mean
changes from baseline to Week 12 for the 3 mg/kg arm
generally indicated little or no negative impact to patient
HRQL across the EORTC QLQ-C30 subscales for global
health status, function, and symptoms. These Phase II
results are similar to the Phase III (MDX010-20) results
and add further support to the effects of ipilimumabtreatment as possibly better or comparable to those
observed in these other clinical trials.
Clinicians are concerned about the effects of treatment
on elderly (i.e., ≥65 years of age) advanced melanoma
patients [46,47]. Although overall survival is comparable
for patients aged <65 and ≥65 years (for ipilimumab
plus gp100 versus gp100 alone, hazard ratio was 0.70
and 0.69 for <65 years and ≥65 years, respectively; for
ipilimumab alone versus gp100 alone, hazard ratio was
0.65 and 0.61 for <65 years and ≥65 years, respectively)
[9], we evaluated differences in HRQL outcomes by age
group. For the ipilimumab plus gp100, results were com-
parable for both age groups, although those ≥65 years
reported more impairment in role function, global
health, and sleep disturbance. For the ipilimumab alone
groups, the results for functional outcome and symptom
scores were comparable, except that those ≥65 years
reported more impairment in social function, dyspnea,
sleep disturbance, and diarrhea.
The HRQL results from the current ipilimumab study
should be interpreted considering the following limita-
tions. HRQL endpoint data were available for only 61% to
65% of patients randomized into the clinical trial. Disease
progression was the most common reason for discontinu-
ation of study drug (24% of subjects in the ipilimumab
plus gp100 group; 16% in the ipilimumab alone group;
and 33% in the gp100 alone group). Rates of discontinu-
ation of study drug due to adverse events were greatest for
ipilimumab alone (13%) compared with ipilimumab plus
gp100 (9%) and gp100 alone (4%). However, there were
comparable completion rates of the EORTC QLQ-C30
across treatment arms in the current study (MDX010-20),
so these missing data may not impact the interpretation of
the HRQL results. Missing HRQL data is a significant
problem for oncology studies, and patients who complete
follow-up assessments are less likely to experience severe
toxicity and are more likely to have better response to
treatment [37]. Finally, although EORTC QLQ-C30 is an
internationally validated, widely used questionnaire for
assessing the HRQL in oncology, melanoma specific
HRQL questions might not have been addressed.
Conclusions
In conclusion, ipilimumab at 3 mg/kg with and without
gp100 vaccine does not have a significant negative im-
pact on HRQL in patients completing the baseline and
Week 12 follow-up, during the treatment induction
phase compared with gp100 alone. Ipilimumab treat-
ment results in little to no impairment in HRQL out-
comes in advanced melanoma patients. The improved
survival observed in the ipilimumab treated groups does
not come with a significant burden on HRQL for
patients in this analysis. Further research is needed to
determine the long term impact of ipilimumab treatment
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needed to better understand the impact of serious adverse
events on HRQL in ipilimumab treated patients.
Additional files
Additional file 1: Methodology for comparison with other melanoma
clinical trials. A systematic search of review articles and clinical trial
articles was conducted in order to compare the HRQL findings from the
ipilimumab studies to other published clinical trials in advanced
melanoma that included the EORTC QLQ-C30. Microsoft Word document
file name: HRQL Melanoma Manuscript Appendix_HQLO_final.doc.
Additional file 2: Figure A1. Baseline to endpoint changes in EORTC
QLQ-C30 function and global health scores for advanced melanoma
studies.
Additional file 3: Figure A2. Baseline to endpoint changes in EORTC
QLQ-C30 symptom scores for advanced melanoma studies.
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